Exercise 20 minutes daily to reduce risk of premature death
the ONA take:
According to a new study published in the American Journal of Clinical Nutrition, researchers at the University of Cambridge in Cambridge, United Kingdom, have found that a sedentary lifestyle is twice as deadly as obesity, but walking for 20 minutes each day can reduce the risk of premature death.
For the study, researchers sought to investigate the link between a sedentary lifestyle and premature death. They analyzed data on over 334,000 Europeans from the European Prospective Investigation into Cancer and Nutrition (EPIC) Study.
All participants were followed for over 12 years and about 21,500 died during that time. Results showed that premature death and physical inactivity were present in participants from all level of overweight and obesity, but those with inactive lifestyles were twice as likely those with obesity to die early.
In addition, analyses showed that doing exercise equivalent to a 20-minute brisk walk can reduce the risk of premature death by 16-30% in those with inactive lifestyles.
This effect was greatest among those with normal weights, but there is also benefit among those overweight and obese. Researchers note that people should do more exercise than a brisk 20-minute walk each day due its proven health benefits.
A sedentary lifestyle is twice as deadly as obesity, but walking for 20 minutes each day can reduce risk of premature death.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|